A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma

  • Jana, Bagi (PI)

    Project: Research project

    Project Details

    StatusActive
    Effective start/end date9/5/18 → 6/16/26

    Funding

    • Janssen Pharmaceutical Research and Development: $13,625.00